New Treatments Compared with Placebo Declining

Share this article:
New Treatments Outperforming Placebo Becoming Less Common
New Treatments Outperforming Placebo Becoming Less Common

The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.

The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

This article originally appeared here.
Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in News

More in News

Clinician-to-Patient Relationship Affects Healthcare Outcomes

Clinician-to-Patient Relationship Affects Healthcare Outcomes

Meta-analysis of 13 randomized controlled trials shows small but significant effect.

NSAIDs Linked to Increased Atrial Fibrillation Risk

NSAIDs Linked to Increased Atrial Fibrillation Risk

Among elderly individuals, increased risk for current, recent use compared with never-use.

Patients Less Likely to Select 'Lower Tier' Doctors

Patients Less Likely to Select 'Lower Tier' Doctors

Tiered networks combined with payment-based reforms can improve performance.